Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Open-Label, Assessor-Blind, Noninferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
Conditions
Interventions
Liprotamase
porcine (pig) PERT
Locations
54
United States
Investigator Site 123
Long Beach, California, United States
Investigator Site 107
Los Angeles, California, United States
Investigator Site 114
Aurora, Colorado, United States
Investigator Site 120
Gainesville, Florida, United States
Investigator Site 102
Jacksonville, Florida, United States
Investigator Site 130
Miami, Florida, United States
Start Date
June 1, 2015
Primary Completion Date
October 1, 2016
Completion Date
January 20, 2017
Last Updated
August 14, 2018
NCT02417740
NCT06616857
NCT07108153
NCT02740868
NCT07274631
NCT07303621
Lead Sponsor
Anthera Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions